Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer
The GEMSTONE-303 trial demonstrated the significant efficacy and safety of sugemalimab plus chemotherapy (S + C) as first-line treatment for patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). To evaluate the cost-effectiveness of S + C for advanced GC/GEJC from th...
Shranjeno v:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2026-12-01
|
| Serija: | Human Vaccines & Immunotherapeutics |
| Teme: | |
| Online dostop: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2611471 |
| Oznake: |
Brez oznak, prvi označite!
|